Market Overview

Robbins Arroyo LLP: Cronos Group Inc. (CRON) Misled Shareholders According to a Recently Filed Class Action


Shareholder rights law firm Robbins
Arroyo LLP
announces that purchasers of Cronos Group Inc. (NasdaqGM:
CRON) have filed a class action complaint against the company's officers
and directors for alleged violations of the Securities Exchange Act of
1934 between August 21, 2018 and August 30, 2018. Cronos is a principal
investment firm.

View this information on the law firm's Shareholder Rights Blog:

Cronos Accused of Deceiving Investors About the Size of Its
Distribution Agreements

According to the complaint, on August 21, 2018, Cronos announced that it
had signed binding master supply agreements with several provinces,
noting that the company was "committed to building strong relationships"
with the provinces and its customers. The following week, on August 30,
2018, Citron Research published an article alleging that Cronos hid the
size of its distribution agreements with provinces because the
agreements were so small that the company could not justify the premium
investors were paying for the stock. Citron also pointed out that
despite having the first license issued by Health Canada in 2013, Cronos
had vastly underperformed every big competitor. On this news, Cronos'
share price fell over 28% to close at $9.12 per share on August 30, 2018.

Cronos Shareholders Have Legal Options

Concerned shareholders who would like more information about their
rights and potential remedies can contact attorney Leonid Kandinov at
(800) 350-6003,,
or via the shareholder
information form
on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder
rights law. The firm represents individual and institutional investors
in shareholder derivative and securities class action lawsuits, and has
helped its clients realize more than $1 billion of value for themselves
and the companies in which they have invested. Sign up for our FREE
portfolio monitoring service, Stock

Attorney Advertising. Past results do not guarantee a similar outcome.

View Comments and Join the Discussion!
Fastest news service for the smartest traders
$147 Free 14 day Trial